| 000 | 01469 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250513041256.0 | ||
| 264 | 0 | _c19950518 | |
| 008 | 199505s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/s0140-6736(95)90699-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKitchen, V S | |
| 245 | 0 | 0 |
_aSafety and activity of saquinavir in HIV infection. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cApr 1995 |
||
| 300 |
_a952-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aHIV _xisolation & purification |
| 650 | 0 | 4 |
_aHIV Infections _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoquinolines _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aQuinolines _xadministration & dosage |
| 650 | 0 | 4 | _aSaquinavir |
| 700 | 1 | _aSkinner, C | |
| 700 | 1 | _aAriyoshi, K | |
| 700 | 1 | _aLane, E A | |
| 700 | 1 | _aDuncan, I B | |
| 700 | 1 | _aBurckhardt, J | |
| 700 | 1 | _aBurger, H U | |
| 700 | 1 | _aBragman, K | |
| 700 | 1 | _aPinching, A J | |
| 700 | 1 | _aWeber, J N | |
| 773 | 0 |
_tLancet (London, England) _gvol. 345 _gno. 8955 _gp. 952-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0140-6736(95)90699-1 _zAvailable from publisher's website |
| 999 |
_c7714684 _d7714684 |
||